Terms: = Ovarian cancer AND MUC16, CA125, CA-125 AND Clinical Outcome
65 results:
1. Immunohistochemical evaluation of forkhead box A1 and EphA5 markers in serous ovarian carcinomas, and their impact on the clinical outcome of patients.
Abouhashem N; Harb O; Elwan A; Zaitoun M; Saraya Y
Pol J Pathol; 2022; 73(2):120-133. PubMed ID: 36345952
[TBL] [Abstract] [Full Text] [Related]
2. High grade, advanced, serous ovarian cancer with low serum ca125 levels.
Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
[TBL] [Abstract] [Full Text] [Related]
3. Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer.
Koole SN; Bruijs L; Fabris C; Sikorska K; Engbersen M; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; van der Velden J; Arts HJG; van Ham M; Van Dam P; Vuylsteke P; Lahaye M; Sonke G; Driel WV
Int J Gynecol Cancer; 2020 Dec; 30(12):1928-1934. PubMed ID: 33046576
[TBL] [Abstract] [Full Text] [Related]
4. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.
Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
[TBL] [Abstract] [Full Text] [Related]
5. ca-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer.
Kessous R; Wissing MD; Piedimonte S; Abitbol J; Kogan L; Laskov I; Yasmeen A; Salvador S; Lau S; Gotlieb WH
Acta Obstet Gynecol Scand; 2020 Jul; 99(7):933-940. PubMed ID: 31954071
[TBL] [Abstract] [Full Text] [Related]
6. Perioperative change in ca125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer.
Timmermans M; Zwakman N; Sonke GS; Van de Vijver KK; Duk MJ; van der Aa MA; Kruitwagen RF
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():364-369. PubMed ID: 31400565
[TBL] [Abstract] [Full Text] [Related]
7. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract] [Full Text] [Related]
8. The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers.
Carvalho VP; Grassi ML; Palma CS; Carrara HHA; Faça VM; Candido Dos Reis FJ; Poersch A
Transl Res; 2019 Apr; 206():71-90. PubMed ID: 30529050
[TBL] [Abstract] [Full Text] [Related]
9. Biomarker Assessment of HR Deficiency, Tumor
Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
[TBL] [Abstract] [Full Text] [Related]
10. GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with ca125 in epithelial ovarian cancer.
Zhao D; Wang X; Zhang W
BMC Cancer; 2018 Mar; 18(1):328. PubMed ID: 29580231
[TBL] [Abstract] [Full Text] [Related]
11. FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed ovarian cancer Exhibiting Low ca125.
Wang W; Somers EB; Ross EN; Kline JB; O'Shannessy DJ; Schweizer C; Weil S; Grasso L; Nicolaides NC
Cytogenet Genome Res; 2017; 152(4):169-179. PubMed ID: 29041009
[TBL] [Abstract] [Full Text] [Related]
12. A 2-Protein Signature Predicting clinical outcome in High-Grade Serous ovarian cancer.
Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
[TBL] [Abstract] [Full Text] [Related]
13. TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
Park GB; Kim D
Oncol Rep; 2017 Nov; 38(5):3167-3176. PubMed ID: 28901470
[TBL] [Abstract] [Full Text] [Related]
14. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.
George A; McLachlan J; Tunariu N; Della Pepa C; Migali C; Gore M; Kaye S; Banerjee S
BMC Cancer; 2017 Jun; 17(1):456. PubMed ID: 28666422
[TBL] [Abstract] [Full Text] [Related]
15. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract] [Full Text] [Related]
16. LAMP3 expression correlated with poor clinical outcome in human ovarian cancer.
Wang D; Cao X; Zhang Y; Liu Y; Yao C; Ge W; Xu Y
Tumour Biol; 2017 Mar; 39(3):1010428317695014. PubMed ID: 28349821
[TBL] [Abstract] [Full Text] [Related]
17. Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer.
Huang CY; Yang YC; Wang KL; Chen TC; Chen JR; Weng CS; Chien HJ; Chang CL
Taiwan J Obstet Gynecol; 2016 Jun; 55(3):405-9. PubMed ID: 27343324
[TBL] [Abstract] [Full Text] [Related]
18. The prognostic value of pretreatment ca-125 levels and ca-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study.
Bai H; Sha G; Xiao M; Gao H; Cao D; Yang J; Chen J; Wang Y; Zhang Z; Shen K
Oncotarget; 2016 Mar; 7(13):15566-76. PubMed ID: 26863639
[TBL] [Abstract] [Full Text] [Related]
19. The gynecological surveillance of women with Lynch syndrome in Sweden.
Tzortzatos G; Andersson E; Soller M; Askmalm MS; Zagoras T; Georgii-Hemming P; Lindblom A; Tham E; Mints M
Gynecol Oncol; 2015 Sep; 138(3):717-22. PubMed ID: 26177554
[TBL] [Abstract] [Full Text] [Related]
20. Expression of the Carboxy-Terminal Portion of muc16/ca125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract] [Full Text] [Related]
[Next]
